dry eye disease

News

Senju launches first-in-class dry eye disease drug in Japan

Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.

News

Palatin pummelled as dry eye therapy underwhelms in phase 3

Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.

News

Aldeyra’s reproxalap for dry eye disease accepted by FDA

Biotech Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New D

Senju launches first-in-class dry eye disease drug in Japan

Palatin pummelled as dry eye therapy underwhelms in phase 3

Aldeyra’s reproxalap for dry eye disease accepted by FDA

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks